NCT04303195: An ongoing trial by Neurogastrx, Inc.
This trial is completed, but has been granted a delay in reporting its results.
It must report results 5 months, 4 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04303195 |
|---|---|
| Title | A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study, of the Safety and Efficacy of NG101 Administered Orally to Patients With Gastroparesis |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 1, 2020 |
| Completion date | Feb. 25, 2023 |
| Required reporting date | Feb. 25, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 28, 2025 |
| Days late | None |